NCT00403325

Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Vitreous -Retina- Macula Consultants of New York · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy.

Detailed description

This is an open-label, Phase I study of intravitreally administered ranibizumab in subjects with unresolving CSC and subfoveal fluid. Patients will be evaluated at baseline with ophthalmic examination, fluorescein angiography, optical coherence tomography, and color photography. Subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered every 28 days (± 2 days) for 3 injections. Thereafter they are to be evaluated every month until month 12. Treatment will be administered to patients if there is presence of active leakage as determined by fluorescein angiography or persistence presence of sub retinal fluid upon OCT examination at that monthly visit.

Conditions

• Central Serous Chorioretinopathy

Interventions

Type	Name	Description
DRUG	rhuFab V2 [ranibizumab] ( Lucentis )

Timeline

• Start date: 2006-08-01
• First posted: 2006-11-23
• Last updated: 2008-11-03

Locations

1 site across 1 country: United States